Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis

Emma Guttman-Yassky, Michelle A. Lowes, Judilyn Fuentes-Duculan, Julia Whynot, Inna Novitskaya, Irma Cardinale, Asifa Haider, Artemis Khatcherian, John A. Carucci, Reuven Bergman, James G. Krueger

Research output: Contribution to journalArticlepeer-review

199 Scopus citations


Background: Atopic dermatitis (AD) and psoriasis represent contrasting poles of the TH1 versus TH2 paradigm. Both diseases have been associated with increased numbers of dendritic cells (DCs) in the skin, but the similarities and differences in DC populations need to be established. Objective: We aimed to characterize the specific DC subsets, as well as chemokine and cytokine environment in chronic AD compared with psoriasis. Methods: Skin biopsies were obtained from patients with acute exacerbation of chronic AD (n = 18), psoriasis (n = 15), and healthy volunteers (n = 15) for microarray analysis, RT-PCR, immunohistochemistry, and double-label immunofluorescence. Results: Myeloid DCs upregulate CCL17 and CCL18 in AD, as opposed to TNF-α and inducible nitric oxide synthase (iNOS) in psoriasis. In our study, we identified cells phenotypically identical to the inflammatory dendritic epidermal cells in the dermis in both diseases, although to a lesser extent in psoriasis. We found substantially higher numbers of dermal CCL22 producing plasmacytoid DCs in AD. The thymic stromal lymphopoietin receptor showed significantly higher expression in AD, whereas the thymic stromal lymphopoietin ligand was upregulated more in psoriasis. Conclusion: There are major differences in myeloid and plasmacytoid subsets of cutaneous DCs and the chemokine/cytokine environment between AD and psoriasis. Distinct subsets within the CD11c+ population may influence polarization through the production of regulatory mediators, including iNOS, TNF, CCL17, and CCL18. Plasmacytoid DCs may also influence TH2 polarization, having a more important role in AD than previously appreciated. Clinical implications: Dermal inflammatory dendritic cells in AD and TNF and iNOS-producing DCs in psoriasis, and/or their regulatory products, may be potential targets for future therapeutic interventions.

Original languageEnglish
Pages (from-to)1210-1217
Number of pages8
JournalJournal of Allergy and Clinical Immunology
Issue number5
StatePublished - May 2007
Externally publishedYes


  • Atopic dermatitis
  • TIP-DCs
  • inflammatory dendritic epidermal cells
  • myeloid DCs
  • plasmacytoid DCs
  • psoriasis


Dive into the research topics of 'Major differences in inflammatory dendritic cells and their products distinguish atopic dermatitis from psoriasis'. Together they form a unique fingerprint.

Cite this